The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger

被引:2
|
作者
Berger, Marc L. [1 ]
机构
[1] SHYFT Analyt, Real World Evidence Advisory Board, Waltham, MA 02453 USA
关键词
evidence generation; evidence planning; health technology assessment; market access; real-world data; real-world evidence; regulatory;
D O I
10.2217/cer-2017-0082
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Marc L Berger, MD, is a retired, part-time consultant. He recently became Chair of the Real World Evidence Advisory Board for SHYFT Analytics. Over a 25-year industry career, Marc has held senior-level positions at Pfizer, Inc., OptumInsight, Eli Lilly and Company, and Merck & Co., Inc. His professional activities have included serving on committees for Center for Medicare and Medicaid Services (CMS), Agency for Healthcare Research and Quality (AHRQ), Patient-Centered Outcomes Research Institute (PCORI), the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Drug Information Association (DIA), and the editorial advisory boards of several journals. Marc has written or co-written more than 100 peer-reviewed articles, book chapters, and other publications on a range of topics including health services research, outcomes research, health economics, health policy, and the analysis of real-world data. © 2018 Future Medicine Ltd.
引用
收藏
页码:11 / 13
页数:3
相关论文
共 34 条
  • [1] Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
    Berger, Marc L.
    Sox, Harold
    Willke, Richard J.
    Brixner, Diana L.
    Eichler, Hans-Georg
    Goettsch, Wim
    Madigan, David
    Makady, Amr
    Schneeweiss, Sebastian
    Tarricone, Rosanna
    Wang, Shirley V.
    Watkins, John
    Daniel Mullins, C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) : 1033 - 1039
  • [2] Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making
    Berger, Marc L.
    Sox, Harold
    Willke, Richard J.
    Brixner, Diana L.
    Eichler, Hans-Georg
    Goettsch, Wim
    Madigan, David
    Makady, Amr
    Schneeweiss, Sebastian
    Tarricone, Rosanna
    Wang, Shirley V.
    Watkins, John
    Mullins, C. Daniel
    VALUE IN HEALTH, 2017, 20 (08) : 1003 - 1008
  • [3] HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force
    Wang, Shirley, V
    Pottegard, Anton
    Crown, William
    Arlett, Peter
    Ashcroft, Darren M.
    Benchimol, Eric, I
    Berger, Marc L.
    Crane, Gracy
    Goettsch, Wim
    Hua, Wei
    Kabadi, Shaum
    Kern, David M.
    Kurz, Xavier
    Langan, Sinead
    Nonaka, Takahiro
    Orsini, Lucinda
    Perez-Gutthann, Susana
    Pinheiro, Simone
    Pratt, Nicole
    Schneeweiss, Sebastian
    Toussi, Massoud
    Williams, Rebecca J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (01) : 44 - 55
  • [4] HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force
    Wang, Shirley, V
    Pottegard, Anton
    Crown, William
    Arlett, Peter
    Ashcroft, Darren M.
    Benchimol, Eric, I
    Berger, Marc L.
    Crane, Gracy
    Goettsch, Wim
    Hua, Wei
    Kabadi, Shaum
    Kern, David M.
    Kurz, Xavier
    Langan, Sinead
    Nonaka, Takahiro
    Orsini, Lucinda
    Perez-Gutthann, Susana
    Pinheiro, Simone
    Pratt, Nicole
    Schneeweiss, Sebastian
    Toussi, Massoud
    Williams, Rebecca J.
    VALUE IN HEALTH, 2022, 25 (10) : 1663 - 1672
  • [5] The Expanding Role of Real-World Evidence Trials in Health Care Decision Making
    Klonoff, David C.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (01): : 174 - 179
  • [6] Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5]
    Phelps, Charles E.
    Lakdawalla, Darius N.
    Basu, Anirban
    Drummond, Michael F.
    Towse, Adrian
    Danzon, Patricia M.
    VALUE IN HEALTH, 2018, 21 (02) : 146 - 154
  • [7] Use of pharmacoeconomics information - Report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making
    Drummond, M
    Brown, R
    Fendrick, AM
    Fullerton, P
    Neumann, P
    Taylor, R
    Barbieri, M
    VALUE IN HEALTH, 2003, 6 (04) : 407 - 416
  • [8] Multiple Criteria Decision Analysis for Health Care Decision Making-An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force
    Thokala, Praveen
    Devlin, Nancy
    Marsh, Kevin
    Baltussen, Rob
    Boysen, Meindert
    Kalo, Zoltan
    Longrenn, Thomas
    Mussen, Filip
    Peacock, Stuart
    Watkins, John
    Ijzerman, Maarten
    VALUE IN HEALTH, 2016, 19 (01) : 1 - 13
  • [9] Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force
    Fleurence, Rachael L.
    Kent, Seamus
    Adamson, Blythe
    Tcheng, James
    Balicer, Ran
    Ross, Joseph S.
    Haynes, Kevin
    Muller, Patrick
    Campbell, Jon
    Bouee-Benhamiche, Elsa
    Marti, Sebastian Garcia
    Ramsey, Scott
    VALUE IN HEALTH, 2024, 27 (06) : 692 - 701
  • [10] Real-world evidence to support health technology assessment and payer decision making: is it now or never?
    Murphy, Linda A.
    Akehurst, Ron
    Cunningham, David
    de Pouvourville, Gerard
    Sola-Morales, Oriol
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2025, 41 (01)